By Janice Staber, MD There have been years when the hemostasis and thrombosis community might have felt a little left behind at the ASH annual meeting. However, here in Orlando, sessions on hemostasis and thrombosis were discussed front and center. From the...
By Lynn Malec, MD, MSc, and Janice Staber, MD From the stock market to politics, keeping gains and losses straight these days can be confusing. Scientific gains and losses can be equally overwhelming. Thankfully, in Monday’s Scientific Spotlight Session on Redox...
By Lynn Malec, MD, MSc, and Janice Staber, MD When one hematologic disorder begets another, unlocking the mystery of the mechanisms of disease is the first crucial step in identifying potential targets for future therapeutic modulation. It is known that hemolytic...
By Basem M. William, MD, MRCP(UK), FACP Donnall Thomas, MD, pioneered the first successful allogeneic bone marrow (BM) trans- plant, and reported on it in the New England Journal of Medicine in 1957, extending hope to many patients with incurable hematologic...
By Binod Dhakal, MD, MS In 1951 a renowned hematologist from Harvard University, William Dameshek, MD, wrote an editorial in Blood providing seminal insight into myeloproliferative neoplasms (MPNs) — a group of disorders characterized by expansion of different myeloid...
Continuing Conversations with the Speakers sessions allow for informal discussions with Scientific Program session speakers that will give interested individuals, especially trainees and junior investigators, increased accessibility both to information on the topic...
By Binod Dhakal, MD, MS The year 1982 heralds the discovery of the first mutated genes to be identified in cancer, RAS. The three RAS genes — KRAS, NRAS, and HRAS — still constitute the most frequently mutated oncogene family in human cancers. However, despite more...
Continuing Conversations With the Speakers sessions allow for informal discussions with Scientific Program session speakers that will give interested individuals, especially trainees and junior investigators, increased accessibility both to information on the topic...
By Basem M. William, MD We have made significant progress in our understanding of the pathogenesis and progression of lymphoma through the molecular dissection of malignant cells. By contrast, the importance of the cellular context in which these malignant cells arise...
By Basem M. William, MD Since Thomas Hodgkin’s initial characterization of lymphomas in 1832 and the first administration of mustard to a patient with lymphoma 100 years later amid the secrecy of a World War II gas program, much has changed. Multiple recurrent themes...
Applying the principles of precision medicine to hematologic diseases is a priority for ASH. Precision medicine encompasses all approaches that use patient- and disease-specific information to prevent, diagnose, and treat a disease. The increasingly widespread use of...
ASH has long recognized the need for comprehensive guidelines and in the past three years has broken ground on developing and/or updating guidelines on several disease types, including venous thromboembolism (VTE), immune thrombocytopenia (ITP), acute myeloid leukemia...
The field of immunotherapy has generated novel immune-based strategies and improved the utility of existing treatment options for various hematologic diseases. As such, ASH has had an enduring interest in improving immunotherapies for all hematologic diseases. This is...
